, China
218 views
Stock photo.

China Life delists from US stock exchange

The insurer said they would apply for ‘voluntary delisting’.

China's state-owned insurer China Life said it would ‘voluntarily delist’ its American depositary shares (ADS) and the deregistration of such ADSs and underlying overseas listed shares (H shares), under the U.S. Securities Exchange Act of 1934 from the New York Stock Exchange (NYSE).

The insurer said that after taking into account a number of considerations, including the limited trading volume of its ADSs relative to the worldwide trading volume of its H Shares, and the considerable administrative costs of maintaining the listing of the ADSs on the NYSE, the registration of the ADSs and the underlying H Shares under the Exchange Act and complying with the periodic reporting requirements and related obligations of the Exchange Act.

ALSO READ: Marine, aviation, and transit insurance in APAC to balloon to $16b by 2026

China Life said that it plans to file for delisting on or after 22 August. The delisting will then take effect ten days after filing, which is on or after 1 September.

China Life in five Chinese state-owned companies who have announced their voluntary delisting from the NYSE. The companies departure comes amidst escalating tension between the two countries.
 

Follow the link for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.